Intervention not reported
All VTE (subgroup analysis open only) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all VTE (subgroup analysis open only) (moderate certainty).
1 finding from 1 review
Intervention not reported
All DVT (subgroup analysis open only) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all DVT (subgroup analysis open only) (moderate certainty).
1 finding from 1 review
Intervention not reported
All VTE (sensitivity analysis unpublished) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all VTE (sensitivity analysis unpublished) (moderate certainty).
1 finding from 1 review
Incidence of recurrent VTE1 after initial treatment (up to 15 days) · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 after initial treatment (up to 15 days) compared with UFH (moderate certainty).
1 finding from 1 review
Recurrent VTE · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 (3 months compared with UFH (moderate certainty).
2 findings from 1 review
Reduction in thrombus size (pre‐ and post‐treatment venograms) · patients with venous thromboembolism.
LMWH may leads to lower reduction in thrombus size (pre‐ and post‐treatment venograms) compared with UFH (low certainty).
1 finding from 1 review
Major bleeding · patients with venous thromboembolism.
LMWH probably leads to lower incidence of major haemorrhagic episodes (during initial treatment ‐… compared with UFH (moderate certainty).
1 finding from 1 review
Overall mortality (end of · patients with venous thromboembolism.
LMWH showed no clear difference in overall mortality (end of compared with UFH (moderate certainty).
1 finding from 1 review
Recurrent VTE · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in incidence of recurrent VTE (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review
Major bleeding · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH may leads to lower incidence of major bleeding (treatment duration 3 months) compared with VKA (low certainty).
1 finding from 1 review
Mortality (treatment duration 3 months) · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in mortality (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review
Intervention not reported
HIT in people undergoing major surgical procedures · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower HIT in people undergoing major surgical procedures (low certainty).
1 finding from 1 review
Intervention not reported
HIT complicated by venous thromboembolism · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower HIT complicated by venous thromboembolism (low certainty).
1 finding from 1 review
Endoscopic remission · patients with induction of remission in ulcerative colitis
It is very uncertain whether LMWH changes endoscopic remission compared with placebo (very low certainty).
1 finding from 1 review
Clinical remission · patients with induction of remission in ulcerative colitis
It is very uncertain whether LMWH + standard therapy changes clinical remission compared with standard therapy (very low certainty).
1 finding from 1 review
Clinical improvement · patients with induction of remission in ulcerative colitis
It is very uncertain whether LMWH + standard therapy changes clinical improvement compared with standard therapy (very low certainty).
1 finding from 1 review
Endoscopic remission · patients with induction of remission in ulcerative colitis
It is very uncertain whether LMWH + standard therapy changes endoscopic remission compared with standard therapy (very low certainty).
1 finding from 1 review
Endoscopic improvement (dichotomous) · patients with induction of remission in ulcerative colitis
It is very uncertain whether LMWH + standard therapy changes endoscopic improvement compared with standard therapy (very low certainty).
1 finding from 1 review
Clinical improvement · patients with induction of remission in ulcerative colitis
It is very uncertain whether UFH changes clinical improvement compared with corticosteroids (very low certainty).
1 finding from 1 review
Pain intensityNumeric pain scale · people with sickle cell disease
1 finding from 1 review